文献速递甲状腺核医学核素与放射性配体治疗放射性药物与辐射防护

放射性碘治疗分化型甲状腺癌诱导的第二原发恶性肿瘤——对现有证据的批判性综述与评估

Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma - a critical review and evaluation of the existing evidence.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-03-23

本综述检索Ovid MEDLINE、Cochrane CENTRAL和PubMed,纳入10项关于放射性碘(RAI)治疗分化型甲状腺癌后第二原发恶性肿瘤(SPM)或剂量-反应关系的研究,采用GRADE评估证据质量。RAI vs 无RAI的SPM相对效应为1.14–1.84,多数无统计学显著性;继发性血液系统恶性肿瘤(SHM)相对效应为1.30–2.50,2/3研究有统计学显著性;7/8研究显示累积RAI活度增加与SPM风险增加相关。证据质量:SPM及剂量-反应关系为“极低”,SHM为“低”。

要点

  • RAI vs 无RAI的SPM相对效应为1.14–1.84,多数结果无统计学显著性。
  • RAI vs 无RAI的SHM相对效应为1.30–2.50,2/3研究有统计学显著性。
  • 7/8研究显示累积RAI活度增加与SPM风险增加相关。

核心结论

  • 基于低质量证据,不能排除SPM风险增加,但预期风险较小。

研究设计与样本

  • 在Ovid MEDLINE、Ovid MEDLINE In-Process & Other Non-Indexed Citations、Ovid MEDLINE Epub Ahead of Print、Cochrane CENTRAL和PubMed进行广泛文献检索。
  • 纳入10项关于RAI诱导SPM或RAI治疗与SPM剂量-反应关系的研究进行分析。
  • 评估每项研究的偏倚风险,并使用GRADE方法判定所有研究的证据质量。

主要发现

  • 对于结局SPM,RAI vs 无RAI的相对效应(相对风险、风险比或比值比)在各研究间为1.14–1.84,但多数结果无统计学显著性。
  • 对于结局SHM,报告的相对效应为1.30–2.50,2/3的研究呈现统计学显著结果。
  • 在7/8的研究中,随着累积RAI活度增加,SPM风险增加。
  • 关于RAI后SPM及剂量-反应关系的证据质量为“极低”,关于RAI后SHM的证据质量为“低”。

关键数值与推荐

  • RAI vs 无RAI的SPM相对效应范围为1.14–1.84,多数无统计学显著性。
  • RAI vs 无RAI的SHM相对效应范围为1.30–2.50,2/3研究有统计学显著性。
  • 7/8研究显示累积RAI活度增加与SPM风险增加相关。
  • 证据质量:SPM及剂量-反应关系为“极低”,SHM为“低”。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 关于RAI后SPM及剂量-反应关系的证据质量为“极低”。
  • 关于RAI后SHM的证据质量为“低”。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Concern is growing about long-term side effects of differentiated thyroid cancer treatment, most notably radioactive iodine (RAI) therapy. However, published studies on the subject have had heterogeneous cohorts and conflicting results. This review seeks to provide an updated evaluation of published evidence, and to elucidate the risk of second primary malignancies (SPMs), especially secondary hematologic malignancies (SHMs), attributable to RAI therapy. METHODS: An extensive literature search was performed in Ovid MEDLINE, Ovid MEDLINE and In-Process & Other Non-Indexed Citations, Ovid MEDLINE Epub Ahead of Print, Cochrane Central Register of Controlled Trials (CENTRAL) and PubMed. Studies regarding RAI-induced SPMs or a dose-response relationship between RAI therapy and SPMs were identified, 10 of which were eligible for the analysis. We evaluated risk of bias in each study and judged quality of evidence (QOE) across all studies using the Grading of Recommendations, Assessment, Development and Evaluations approach. RESULTS: For the outcome "SPM", the relative effect (relative risk, hazard ratio, or odds ratio) of RAI vs. no RAI ranged from 1.14 to 1.84 across studies, but most results were not statistically significant. For the outcome "SHM", reported relative effects ranged from 1.30 to 2.50, with 2/3 of the studies presenting statistically significant results. In 7/8 of the studies, increased risk for SPM was shown with increasing cumulative RAI activity. QOE was "very low" regarding SPM after RAI and regarding a dose-response relationship, and "low" for SHM after RAI. CONCLUSION: Based on low quality evidence, an excess risk for the development of SPM cannot be excluded but is expected to be small.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Reinecke MJ, Ahlers G, Burchert A, et al. Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma - a critical review and evaluation of the existing evidence. Eur J Nucl Med Mol Imaging. 2022. PMID: 35320386. doi:10.1007/s00259-022-05762-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。